

SUPPLEMENT

Lipoprotein (a) Cellular Uptake *ex-vivo* and Hepatic Capture *in-vivo* is

Insensitive to PCSK9 Inhibition with Alirocumab

Chemello et al.

Supplemental Table 1 - Analytical parameters used for each proteotypic peptide.

Protein	Species	Peptide	Fragment	Cone/collision (V)	MRM (<i>m/z</i>)
ApoB100	Human	ATGVLYDYVNK	y ₆ ⁺	34/23	622.4 → 915.6
	Human IS	ATGVLYDYVN-[¹³ C ₆ ¹⁵ N ₂]K	y ₆ ⁺	34/23	623.9 → 915.6
	Mouse	DFSWEETGLK	y ₇ ⁺	30/22	663.2 → 862.5
	Mouse IS	DFSWEETGL-[¹³ C ₆ ¹⁵ N ₂]K	y ₇ ⁺	30/22	667.2 → 870.5
Apo(a)	Human	LFLEPTQADIALLK	y ₁₀ ⁺	57/27	786.9 → 1069.7
	Human SI	LFLEPTQADIALL-[¹³ C ₆ ¹⁵ N ₂]K	y ₁₀ ⁺	57/27	790.8 → 1077.7
Kringle IV	Human	GTYSTTVTGR	y ₇ ⁺	35/22	522.0 → 721.6
	Human SI	GTYSTTVTG-[¹³ C ₆ ¹⁵ N ₄]R	y ₇ ⁺	35/22	527.2 → 731.4

Supplemental Figure 1 - Lipoprotein distribution in the plasma of wild-type (black) and FRG mice (grey). Lipoproteins were separated from 40 μL of plasma by FPLC. Cholesterol concentrations (y-axis) were measured in the eluted fractions. LDL elute between fractions 15 and 25. HDL elute between fractions 25 and 35.



